Neuronetics (STIM)
Market Price (9/13/2026): $3.04 | Market Cap: $222.3 MilSector: Health Care | Industry: Life Sciences Tools & Services
Neuronetics (STIM)
Market Price (9/13/2026): $3.04Market Cap: $222.3 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 40% Megatrend and thematic driversMegatrends include Neuroscience & Brain Health, and Medical Device Innovation. Themes include Neuromodulation Therapies, Mental Health Technology, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -15% Stock price has recently run up significantly6M Rtn6 month market price return is 134% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.3% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 115% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% High stock price volatilityVol 12M is 115% Key risksSTIM key risks include [1] its documented history of financial losses and challenges in achieving profitability and [2] a heavy revenue reliance on its single NeuroStar Advanced Therapy System. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 40% |
| Megatrend and thematic driversMegatrends include Neuroscience & Brain Health, and Medical Device Innovation. Themes include Neuromodulation Therapies, Mental Health Technology, Show more. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -15% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 134% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.3% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 115% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% |
| High stock price volatilityVol 12M is 115% |
| Key risksSTIM key risks include [1] its documented history of financial losses and challenges in achieving profitability and [2] a heavy revenue reliance on its single NeuroStar Advanced Therapy System. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/9/2026
Neuronetics (STIM) stock has gained about 95% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Neuronetics reported total revenue of $41.6 million for fiscal Q2 2026, an increase of 9.1% compared to the second quarter of 2025, surpassing analyst consensus of $40.11 million. The company posted an adjusted loss of $0.05 per share, significantly beating expectations for a $0.12 loss by 58%. This quarter also saw gross margin expand to 51.1% from 46.6% in the prior year, and adjusted EBITDA turned positive at $0.3 million, a notable improvement from a $5.6 million loss in fiscal Q2 2025. These results led to a substantial stock surge, including a 47.24% increase on August 11, 2026, the day the earnings were reported.
2. Robust Growth in Greenbrook Segment and Strategic Evolution of NeuroStar Commercial Model.
The Greenbrook clinic network demonstrated strong growth, with revenue climbing 16.8% year-over-year to $26.9 million in fiscal Q2 2026, making it the primary growth driver and accounting for approximately two-thirds of quarterly revenue. Concurrently, Neuronetics initiated a strategic shift in its NeuroStar business by piloting an expanded set of commercial models, including Capital, Lease, and Sessions options, to broaden customer access and simplify adoption, although NeuroStar revenue saw a slight decline of 2.7% to $14.7 million.
Show more
Neuronetics (STIM) stock has gained about 95% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Neuronetics reported total revenue of $41.6 million for fiscal Q2 2026, an increase of 9.1% compared to the second quarter of 2025, surpassing analyst consensus of $40.11 million. The company posted an adjusted loss of $0.05 per share, significantly beating expectations for a $0.12 loss by 58%. This quarter also saw gross margin expand to 51.1% from 46.6% in the prior year, and adjusted EBITDA turned positive at $0.3 million, a notable improvement from a $5.6 million loss in fiscal Q2 2025. These results led to a substantial stock surge, including a 47.24% increase on August 11, 2026, the day the earnings were reported.
2. Robust Growth in Greenbrook Segment and Strategic Evolution of NeuroStar Commercial Model.
The Greenbrook clinic network demonstrated strong growth, with revenue climbing 16.8% year-over-year to $26.9 million in fiscal Q2 2026, making it the primary growth driver and accounting for approximately two-thirds of quarterly revenue. Concurrently, Neuronetics initiated a strategic shift in its NeuroStar business by piloting an expanded set of commercial models, including Capital, Lease, and Sessions options, to broaden customer access and simplify adoption, although NeuroStar revenue saw a slight decline of 2.7% to $14.7 million.
Show more
Updated on 9/9/2026
Neuronetics (STIM) stock has gained about 95% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Neuronetics reported total revenue of $41.6 million for fiscal Q2 2026, an increase of 9.1% compared to the second quarter of 2025, surpassing analyst consensus of $40.11 million. The company posted an adjusted loss of $0.05 per share, significantly beating expectations for a $0.12 loss by 58%. This quarter also saw gross margin expand to 51.1% from 46.6% in the prior year, and adjusted EBITDA turned positive at $0.3 million, a notable improvement from a $5.6 million loss in fiscal Q2 2025. These results led to a substantial stock surge, including a 47.24% increase on August 11, 2026, the day the earnings were reported.
2. Robust Growth in Greenbrook Segment and Strategic Evolution of NeuroStar Commercial Model.
The Greenbrook clinic network demonstrated strong growth, with revenue climbing 16.8% year-over-year to $26.9 million in fiscal Q2 2026, making it the primary growth driver and accounting for approximately two-thirds of quarterly revenue. Concurrently, Neuronetics initiated a strategic shift in its NeuroStar business by piloting an expanded set of commercial models, including Capital, Lease, and Sessions options, to broaden customer access and simplify adoption, although NeuroStar revenue saw a slight decline of 2.7% to $14.7 million.
3. Positive Analyst Sentiment and Increased Price Targets.
Following the encouraging fiscal Q2 2026 results, financial analysts significantly upgraded their sentiment and price targets for Neuronetics. The average price target rose 33% to $6.00. Multiple analysts issued a "Strong Buy" consensus rating, with price targets ranging up to $7.00. For example, BTIG initiated coverage with a "Buy" rating and a $5 price target, contributing to increased investor confidence.
4. Strategic Partnership to Enhance NeuroStar TMS Therapy.
In May 2026, just prior to the specified period, Neuronetics announced a strategic collaboration with ANT Neuro to integrate its FDA-cleared visor2™ neuronavigation system with the NeuroStar TMS system. This partnership aims to enhance treatment visualization, consistency, and personalization for healthcare providers, reflecting Neuronetics' focus on innovation and expanding the capabilities available to NeuroStar providers within the evolving transcranial magnetic stimulation (TMS) market.
Show less
Neuronetics (STIM) stock has gained about 95% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Financial Performance Exceeding Expectations.
Neuronetics reported total revenue of $41.6 million for fiscal Q2 2026, an increase of 9.1% compared to the second quarter of 2025, surpassing analyst consensus of $40.11 million. The company posted an adjusted loss of $0.05 per share, significantly beating expectations for a $0.12 loss by 58%. This quarter also saw gross margin expand to 51.1% from 46.6% in the prior year, and adjusted EBITDA turned positive at $0.3 million, a notable improvement from a $5.6 million loss in fiscal Q2 2025. These results led to a substantial stock surge, including a 47.24% increase on August 11, 2026, the day the earnings were reported.
2. Robust Growth in Greenbrook Segment and Strategic Evolution of NeuroStar Commercial Model.
The Greenbrook clinic network demonstrated strong growth, with revenue climbing 16.8% year-over-year to $26.9 million in fiscal Q2 2026, making it the primary growth driver and accounting for approximately two-thirds of quarterly revenue. Concurrently, Neuronetics initiated a strategic shift in its NeuroStar business by piloting an expanded set of commercial models, including Capital, Lease, and Sessions options, to broaden customer access and simplify adoption, although NeuroStar revenue saw a slight decline of 2.7% to $14.7 million.
3. Positive Analyst Sentiment and Increased Price Targets.
Following the encouraging fiscal Q2 2026 results, financial analysts significantly upgraded their sentiment and price targets for Neuronetics. The average price target rose 33% to $6.00. Multiple analysts issued a "Strong Buy" consensus rating, with price targets ranging up to $7.00. For example, BTIG initiated coverage with a "Buy" rating and a $5 price target, contributing to increased investor confidence.
4. Strategic Partnership to Enhance NeuroStar TMS Therapy.
In May 2026, just prior to the specified period, Neuronetics announced a strategic collaboration with ANT Neuro to integrate its FDA-cleared visor2™ neuronavigation system with the NeuroStar TMS system. This partnership aims to enhance treatment visualization, consistency, and personalization for healthcare providers, reflecting Neuronetics' focus on innovation and expanding the capabilities available to NeuroStar providers within the evolving transcranial magnetic stimulation (TMS) market.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 96.8% change in STIM stock from 5/31/2026 to 9/12/2026 was primarily driven by a 102.1% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.54 | 3.03 | 96.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 152 | 155 | 2.3% |
| P/S Multiple | 0.7 | 1.4 | 102.1% |
| Shares Outstanding (Mil) | 70 | 73 | -4.8% |
| Cumulative Contribution | 96.8% |
Market Drivers
5/31/2026 to 9/12/2026| Return | Correlation | |
|---|---|---|
| STIM | 96.8% | |
| Market (SPY) | 1.0% | 18.3% |
| Sector (XLV) | 10.6% | -10.9% |
Fundamental Drivers
The 126.1% change in STIM stock from 2/28/2026 to 9/12/2026 was primarily driven by a 105.7% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.34 | 3.03 | 126.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 130 | 155 | 19.4% |
| P/S Multiple | 0.7 | 1.4 | 105.7% |
| Shares Outstanding (Mil) | 67 | 73 | -8.0% |
| Cumulative Contribution | 126.1% |
Market Drivers
2/28/2026 to 9/12/2026| Return | Correlation | |
|---|---|---|
| STIM | 126.1% | |
| Market (SPY) | 11.7% | 17.5% |
| Sector (XLV) | 3.6% | -0.5% |
Fundamental Drivers
The -9.0% change in STIM stock from 8/31/2025 to 9/12/2026 was primarily driven by a -28.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.33 | 3.03 | -9.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 111 | 155 | 39.6% |
| P/S Multiple | 2.0 | 1.4 | -28.0% |
| Shares Outstanding (Mil) | 66 | 73 | -9.5% |
| Cumulative Contribution | -9.0% |
Market Drivers
8/31/2025 to 9/12/2026| Return | Correlation | |
|---|---|---|
| STIM | -9.0% | |
| Market (SPY) | 19.5% | 22.5% |
| Sector (XLV) | 21.9% | 10.0% |
Fundamental Drivers
The 84.8% change in STIM stock from 8/31/2023 to 9/12/2026 was primarily driven by a 128.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.64 | 3.03 | 84.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 68 | 155 | 128.6% |
| P/S Multiple | 0.7 | 1.4 | 106.7% |
| Shares Outstanding (Mil) | 29 | 73 | -60.9% |
| Cumulative Contribution | 84.8% |
Market Drivers
8/31/2023 to 9/12/2026| Return | Correlation | |
|---|---|---|
| STIM | 84.8% | |
| Market (SPY) | 75.7% | 23.2% |
| Sector (XLV) | 30.0% | 13.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STIM Return | -60% | 54% | -58% | -44% | -14% | 118% | -73% |
| Peers Return | -3% | 25% | -4% | -3% | 65% | 24% | 131% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| STIM Win Rate | 33% | 50% | 25% | 42% | 33% | 67% | |
| Peers Win Rate | 53% | 56% | 47% | 47% | 64% | 59% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| STIM Max Drawdown | -82% | -54% | -85% | -87% | -77% | -47% | |
| Peers Max Drawdown | -35% | -39% | -28% | -26% | -26% | -17% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LIVN, AXSM, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/11/2026 (YTD)
How Low Can It Go
| Event | STIM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.6% | -18.8% |
| % Gain to Breakeven | 34.3% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -60.1% | -7.8% |
| % Gain to Breakeven | 150.4% | 8.5% |
| Time to Breakeven | 153 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.0% | -9.5% |
| % Gain to Breakeven | 88.6% | 10.5% |
| Time to Breakeven | 36 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -53.8% | -24.5% |
| % Gain to Breakeven | 116.3% | 32.4% |
| Time to Breakeven | 86 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -61.3% | -33.7% |
| % Gain to Breakeven | 158.6% | 50.9% |
| Time to Breakeven | 136 days | 140 days |
In The Past
Neuronetics's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | STIM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.6% | -18.8% |
| % Gain to Breakeven | 34.3% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -60.1% | -7.8% |
| % Gain to Breakeven | 150.4% | 8.5% |
| Time to Breakeven | 153 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -47.0% | -9.5% |
| % Gain to Breakeven | 88.6% | 10.5% |
| Time to Breakeven | 36 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -53.8% | -24.5% |
| % Gain to Breakeven | 116.3% | 32.4% |
| Time to Breakeven | 86 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -61.3% | -33.7% |
| % Gain to Breakeven | 158.6% | 50.9% |
| Time to Breakeven | 136 days | 140 days |
In The Past
Neuronetics's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Neuronetics (STIM)
Neuronetics, Inc. (STIM) is a commercial-stage medical technology company dedicated to developing and marketing products for patients suffering from neurohealth disorders. The company's core focus is on providing innovative, non-invasive treatment options that can be administered in an office setting, addressing critical needs in mental health.
The company's primary product is the NeuroStar Advanced Therapy System. This system offers a non-invasive and non-systemic treatment specifically designed for adult patients diagnosed with major depressive disorder (MDD). The NeuroStar system operates using transcranial magnetic stimulation (TMS) technology, which generates a pulsed, MRI-strength magnetic field to induce electrical currents in targeted brain areas associated with mood regulation.
Neuronetics sells its NeuroStar Advanced Therapy System directly to psychiatrists through its specialized sales and customer support teams. These psychiatrists then offer the treatment to their patients, primarily serving the mental health market in the United States and internationally.
AI Analysis | Feedback
Here are 1-3 brief analogies for Neuronetics (STIM):
- Like a device-focused **Eli Lilly or Pfizer for depression**, using magnetic stimulation instead of medication.
- Similar to **Intuitive Surgical (maker of da Vinci robots) for brain stimulation in mental health**, providing a specialized non-invasive device for treatment.
- Think of them as the **Align Technology (Invisalign) for brain health**, offering a non-invasive physical device to treat major depressive disorder.
AI Analysis | Feedback
- NeuroStar Advanced Therapy System: This system is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation to treat adult patients with major depressive disorder.
AI Analysis | Feedback
Neuronetics, Inc. (STIM) primarily sells its NeuroStar Advanced Therapy System to **psychiatrists**. These customers are typically individual psychiatrists in private practice, psychiatric clinics, group practices, or hospitals and larger healthcare systems with psychiatry departments.
Since these customers are generally not large, publicly traded companies, specific names of major customer companies and their symbols cannot be provided. Instead, the company serves the following categories of customers:
- Psychiatrists operating private practices.
- Psychiatric clinics and group practices.
- Hospitals and other healthcare institutions with psychiatry departments.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here is the management team for Neuronetics (symbol: STIM):
Keith J. Sullivan, President & Chief Executive Officer
Mr. Sullivan was appointed CEO in July 2020. He brings over three decades of experience in the medical device industry. Prior to joining Neuronetics, he served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company, until its acquisition by Allergan, Inc. in April 2017. He also held leadership positions at Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center, and Coherent Medical. Mr. Sullivan currently serves on the Board of Directors of Venus Concept. He announced his intention to retire effective June 30, 2026.
Steven Pfanstiel, Executive Vice President, Chief Financial Officer, and Treasurer
Mr. Pfanstiel was appointed as Neuronetics' CFO, effective July 15, 2025. He has over 20 years of financial expertise in the healthcare sector. Before joining Neuronetics, he served as the Chief Financial Officer at Marinus Pharmaceuticals.
W. Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary
Mr. Macan is listed as an Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary for Neuronetics. His background includes serving as General Counsel for the company.
Cory Anderson, Vice President, Clinical Affairs and Medical Operations
Mr. Anderson was appointed Vice President, Clinical Affairs and Medical Operations in March 2021, taking on interim leadership of R&D and clinical functions. He brings over 20 years of medical technology experience and executive leadership from medical device startup companies. Prior to Neuronetics, he was Vice President, Business Development and Marketing (Corporate Officer) at Sebacia, where he led phase IV clinical trials and guided the R&D pipeline. He also served as VP Business Development at The Innovation Factory and a Principal at Accuitive Medical Ventures, an early investor in Neuronetics.
AI Analysis | Feedback
The key risks to Neuronetics' business include its ongoing financial challenges, heavy reliance on its NeuroStar Advanced Therapy System, and the combined pressures of regulatory uncertainty, reimbursement policies, and a competitive market.
- Financial Challenges and History of Losses: Neuronetics has a history of operating losses and faces significant challenges in achieving and sustaining profitability. The company's financial strength is rated as poor, with high debt levels and an Altman Z-Score indicating potential financial distress. Despite projected revenue growth, the company is expected to remain unprofitable for at least the next three years, grappling with negative operating and net margins, and high operating expenses.
- Heavy Reliance on NeuroStar Advanced Therapy System: The company's revenue is predominantly generated from the NeuroStar system, making it highly vulnerable to market fluctuations, competitive pressures, or any developments that could impact the product's standing. While Neuronetics is exploring new indications and expanding its market, this dependence on a single core product is a significant concentration risk.
- Regulatory, Reimbursement, and Competitive Pressures: Neuronetics operates in a highly regulated medical technology sector and faces ongoing risks related to changes in healthcare regulations and the process of obtaining and maintaining regulatory approvals for its devices and expanded indications. Furthermore, the availability and adequacy of coverage and reimbursement from third-party payors are critical for patient access and revenue growth. The company also operates within a competitive landscape with other transcranial magnetic stimulation (TMS) device manufacturers, such as BrainsWay and MagVenture, which can impact market share and pricing.
AI Analysis | Feedback
null
AI Analysis | Feedback
Neuronetics, Inc. (STIM) primarily offers the NeuroStar Advanced Therapy System for the treatment of Major Depressive Disorder (MDD).
The addressable market for their main product, NeuroStar Advanced Therapy for MDD, is approximately 29.3 million patients in the United States. This figure increased by approximately 35% with the addition of the adolescent indication (ages 15-21) for MDD in March 2024. Previously, the adult MDD market in the U.S. was estimated at 21 million Americans.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Neuronetics (STIM) Over the Next 2-3 Years
Neuronetics (NASDAQ: STIM) is positioned for future revenue growth over the next two to three years, driven by several strategic initiatives and market expansions.- Synergies and Expanded Clinic Network from Greenbrook TMS Acquisition: The acquisition and successful integration of Greenbrook TMS in December 2024 is a primary driver of revenue growth. This strategic move transformed Neuronetics into a vertically integrated company, adding over 95 treatment clinics across the United States. The integration is expected to yield substantial revenue contributions from clinic operations, enhance operational efficiencies, and realize annualized cost synergies.
- Expansion into the Adolescent Depression Market: The FDA clearance of NeuroStar Advanced Therapy as a first-line add-on treatment for adolescents (aged 15-21) with major depressive disorder (MDD) significantly broadens Neuronetics' addressable market. This expansion is projected to increase the total addressable market by approximately 35%, opening up a new and substantial patient demographic for NeuroStar therapy.
- Increased Utilization and Patient Volume within Existing and New Clinics: Growth in treatment session volume for NeuroStar systems and higher patient volumes at Greenbrook clinics are anticipated to drive revenue. Initiatives such as the "Better Me Provider (BMP) program," launched in July 2024, are designed to enhance patient care and accessibility, leading to a greater number of patients receiving treatment and increasing the utilization of NeuroStar devices.
- Capital Sales of NeuroStar Advanced Therapy Systems: The continued sale and placement of NeuroStar systems to psychiatrists and clinics remain a critical revenue driver. While there can be quarterly fluctuations in system sales, the company aims for consistent shipments and has demonstrated strong average selling prices per system, contributing to initial capital revenue and subsequent recurring revenue from proprietary treatment session consumables. Strategic initiatives like NeuroStar summits further support system adoption.
AI Analysis | Feedback
Share Issuance
- In January 2021, Neuronetics conducted a public offering of 4,840,000 shares of common stock at $15.50 per share, raising approximately $75.0 million in gross proceeds, intended for general corporate purposes including working capital, research and development, and marketing.
- In February 2025, the company priced an underwritten public offering of 8,000,000 shares of common stock at $2.25 per share, generating approximately $18 million in gross proceeds. The net proceeds from this offering were earmarked for general corporate purposes, including sales and marketing, research and development activities, and potential acquisitions.
- During the period ended September 30, 2025, Neuronetics sold 2,261,835 shares through its At-the-Market (ATM) facility at an average price of $3.68 per share, resulting in gross proceeds of $8.3 million and net proceeds of approximately $7.8 million for general corporate purposes and growth initiatives.
Outbound Investments
- In December 2024, Neuronetics completed the acquisition of Greenbrook, a transaction that made Greenbrook a wholly-owned subsidiary of Neuronetics. This acquisition significantly impacted Neuronetics' revenue and operational structure in subsequent financial reporting.
Capital Expenditures
- Net proceeds from the February 2025 public offering of common stock were intended, in part, for capital expenditures, alongside other general corporate purposes.
Peer Outperformance in Life Sciences Tools & Services
STIM has outperformed 63% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is GH. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that STIM has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
49%
of 127 industry peers · -3.0% return
3Y
82%
of 117 industry peers · 107.5% return
5Y
63%
of 108 industry peers · -55.4% return
Life Sciences Tools & Services peers with revenue growth within 4pp of STIM's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| STIM | Neuronetics | 33.3% | -7.3x | -3.0% | 107.5% | -55.4% | — |
| GH | Guardant Health | 32.6% | -46.1x | 186.7% | 388.0% | 24.4% | +80pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is STIM's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 7.1% | 86.6% | 123.6% | CAH 394% · MCK 338% · COR 174% |
| Managed Health Care | 8 | 43.7% | -1.7% | 5.5% | OSCR 92% · HQY 50% · ELV 22% |
| Health Care Services | 20 | 18.9% | 44.9% | -1.2% | HIMS 210% · RDNT 167% · DGX 68% |
| Health Care Facilities | 24 | 3.7% | 8.8% | -15.4% | NHC 274% · THC 258% · ENSG 119% |
| Health Care Equipment | 50 | -1.7% | -5.7% | -25.4% | POCI 10800% · UFPT 324% · GKOS 233% |
| Health Care Supplies | 12 | 20.8% | -12.4% | -38.0% | LNTH 300% · HAE 51% · MMSI 21% |
| Pharmaceuticals | 62 | -7.4% | 7.5% | -41.2% | LQDA 2363% · INDV 1136% · ETON 1026% |
| Life Sciences Tools & Services ← | 109 | -1.4% | -26.6% | -71.9% | SNWV 1573% · MEDP 217% · NTRA 174% |
| Health Care Technology | 20 | -31.7% | -51.5% | -79.2% | SPOK 79% · HSTM 2% · VEEV -12% |
| Biotechnology | 361 | 1.6% | -25.2% | -79.6% | DNTH 1596% · CELZ 1272% · ELVN 1178% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Neuronetics Earnings Notes | 12/16/2025 | |
| Would You Still Hold Neuronetics Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 149.47 |
| Mkt Cap | 7.9 |
| Rev LTM | 1,124 |
| Op Inc LTM | 82 |
| FCF LTM | 69 |
| FCF 3Y Avg | 54 |
| CFO LTM | 119 |
| CFO 3Y Avg | 87 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 26.0% |
| Rev Chg 3Y Avg | 22.0% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 16.8% |
| Op Inc Chg 3Y Avg | 6.4% |
| Op Mgn LTM | -1.0% |
| Op Mgn 3Y Avg | -9.6% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 5.1% |
| CFO/Rev 3Y Avg | -4.8% |
| FCF/Rev LTM | 1.4% |
| FCF/Rev 3Y Avg | -7.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Clinic Service | 87 | 4 | 0 | ||
| Med Device | 62 | 70 | 71 | ||
| NeuroStar Advanced Therapy System-International | 1 | 1 | |||
| NeuroStar Advanced Therapy System-United States | 17 | 10 | |||
| Other-International | 1 | 0 | |||
| Other-United States | 2 | 2 | |||
| Treatment sessions-International | 0 | 0 | |||
| Treatment sessions-United States | 45 | 42 | |||
| Total | 149 | 75 | 71 | 65 | 55 |
Price Behavior
Price Behavior
| Market Price | $3.03 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 06/28/2018 | |
| Distance from 52W High | -8.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.41 | $1.73 |
| DMA Trend | up | up |
| Distance from DMA | 25.5% | 75.4% |
| 3M | 1YR | |
| Volatility | 126.9% | 115.4% |
| Downside Capture | -291.08 | 132.38 |
| Upside Capture | 161.50 | 104.17 |
| Correlation (SPY) | 8.7% | 22.5% |
STIM Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.89 | 2.30 | 2.02 | 1.71 | 2.14 | 1.71 |
| Up Beta | 4.68 | 4.74 | 2.37 | 2.28 | 2.44 | 1.71 |
| Down Beta | 1.27 | 7.57 | 5.24 | 3.16 | 3.77 | 1.52 |
| Up Capture | 239% | 376% | 267% | 217% | 136% | 699% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 9 | 21 | 33 | 62 | 118 | 346 |
| Down Capture | -656% | -408% | -74% | 31% | 142% | 111% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 12 | 21 | 30 | 59 | 126 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STIM | |
|---|---|---|---|---|
| STIM | -12.2% | 115.4% | 0.39 | - |
| Sector ETF (XLV) | 22.1% | 16.2% | 1.04 | 9.7% |
| Equity (SPY) | 18.3% | 12.8% | 1.03 | 22.4% |
| Gold (GLD) | 19.0% | 29.2% | 0.59 | 3.0% |
| Commodities (DBC) | 48.3% | 20.6% | 1.80 | -6.5% |
| Real Estate (VNQ) | 7.6% | 13.6% | 0.29 | 1.8% |
| Bitcoin (BTCUSD) | -32.4% | 43.8% | -0.77 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STIM | |
|---|---|---|---|---|
| STIM | -16.9% | 98.1% | 0.28 | - |
| Sector ETF (XLV) | 5.5% | 15.2% | 0.18 | 17.3% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 25.3% |
| Gold (GLD) | 18.7% | 18.8% | 0.81 | 1.9% |
| Commodities (DBC) | 11.4% | 19.5% | 0.46 | 3.4% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 16.4% |
| Bitcoin (BTCUSD) | 9.4% | 52.6% | 0.36 | 9.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STIM | |
|---|---|---|---|---|
| STIM | -19.8% | 96.6% | 0.19 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 20.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 26.9% |
| Gold (GLD) | 12.3% | 16.3% | 0.62 | 1.6% |
| Commodities (DBC) | 8.7% | 18.1% | 0.39 | 7.3% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 21.4% |
| Bitcoin (BTCUSD) | 63.2% | 66.2% | 1.03 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/13/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 47.0% | 50.7% | 40.1% |
| 5/5/2026 | 7.4% | -25.5% | -31.2% |
| 3/17/2026 | -9.9% | 17.6% | 2.2% |
| 11/4/2025 | 3.6% | -22.7% | -47.7% |
| 8/5/2025 | -2.5% | -15.9% | -29.8% |
| 5/6/2025 | 0.0% | -8.0% | -13.8% |
| 3/4/2025 | 18.8% | 1.6% | -11.3% |
| 1/13/2025 | 36.8% | 43.9% | 129.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 15 | 14 |
| # Negative | 12 | 14 | 15 |
| Median Positive | 9.4% | 21.8% | 43.5% |
| Median Negative | -9.5% | -20.2% | -26.4% |
| Max Positive | 47.0% | 51.6% | 129.8% |
| Max Negative | -58.1% | -44.0% | -56.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 47.0% | 50.7% | 40.1% |
| 5/5/2026 | 7.4% | -25.5% | -31.2% |
| 3/17/2026 | -9.9% | 17.6% | 2.2% |
| 11/4/2025 | 3.6% | -22.7% | -47.7% |
| 8/5/2025 | -2.5% | -15.9% | -29.8% |
| 5/6/2025 | 0.0% | -8.0% | -13.8% |
| 3/4/2025 | 18.8% | 1.6% | -11.3% |
| 1/13/2025 | 36.8% | 43.9% | 129.8% |
| 11/12/2024 | -37.3% | -29.0% | 9.1% |
| 8/12/2024 | -58.1% | -37.1% | -56.2% |
| 5/7/2024 | -30.7% | -31.7% | -49.1% |
| 3/5/2024 | 15.4% | 51.6% | 52.0% |
| 1/8/2024 | -6.4% | 1.7% | 17.7% |
| 11/7/2023 | 8.1% | -3.5% | 45.9% |
| 8/8/2023 | -0.5% | -8.7% | -15.8% |
| 5/9/2023 | 27.3% | 28.2% | 11.8% |
| 3/7/2023 | -19.2% | -44.0% | -48.4% |
| 1/9/2023 | -0.9% | -5.8% | -9.9% |
| 11/8/2022 | 0.5% | 26.5% | 68.6% |
| 8/2/2022 | 0.0% | 0.5% | -12.9% |
| 5/12/2022 | 8.1% | 12.9% | 66.5% |
| 3/8/2022 | 1.1% | 6.3% | 14.4% |
| 1/10/2022 | 14.9% | 6.6% | -16.2% |
| 11/9/2021 | -1.2% | -17.7% | -18.6% |
| 8/3/2021 | -42.0% | -31.6% | -48.4% |
| 5/4/2021 | 39.2% | 28.6% | 41.0% |
| 3/2/2021 | -9.1% | -16.9% | -26.4% |
| 1/13/2021 | 22.3% | 42.2% | 52.1% |
| 11/2/2020 | 9.4% | 21.8% | 50.2% |
| SUMMARY STATS | |||
| # Positive | 17 | 15 | 14 |
| # Negative | 12 | 14 | 15 |
| Median Positive | 9.4% | 21.8% | 43.5% |
| Median Negative | -9.5% | -20.2% | -26.4% |
| Max Positive | 47.0% | 51.6% | 129.8% |
| Max Negative | -58.1% | -44.0% | -56.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/03/2021 | 10-Q |
| 03/31/2021 | 05/04/2021 | 10-Q |
| 12/31/2020 | 03/02/2021 | 10-K |
| 09/30/2020 | 11/02/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 05/05/2020 | 10-Q |
| 12/31/2019 | 03/03/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
Recent Forward Guidance
Updated 8/12/2026Latest: Q2 2026 Earnings Reported 8/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Cash flow from operations and investing | Reported | -14.50 Mil | -12.50 Mil | -10.50 Mil | -16.7% | Raised | Guidance: -15.00 Mil for 2026 | |
| 2026 Total Revenue | Reported | 160.00 Mil | 162.00 Mil | 164.00 Mil | -0.6% | Lowered | Guidance: 163.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 76.80 Mil | 79.38 Mil | 82.00 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 48.0% | 49.0% | 50.0% | 1.0% | Raised | Guidance: 48.0% for 2026 | |
| 2026 Operating Expenses | Reported | 95.00 Mil | 97.50 Mil | 100.00 Mil | -4.9% | Lowered | Guidance: 102.50 Mil for 2026 | |
| 2026 Operating Expenses, less SBC | Reported | 91.00 Mil | 93.50 Mil | 96.00 Mil | ||||
| 2026 Operating Income | Calculated | -23.20 Mil | -18.12 Mil | -13.00 Mil | Rev x Gross Margin - Opex | |||
| 2026 Operating Margin | Calculated | -14.5% | -11.19% | -7.93% | Implied by guided Rev/GM/Opex | |||
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Total Revenue Growth | Reported | 5.0% | ||||||
| 2026 Cash Flow from Operations | Reported | -17.00 Mil | -15.00 Mil | -13.00 Mil | 0 | Affirmed | Guidance: -15.00 Mil for 2026 | |
| 2026 Revenue | Reported | 160.00 Mil | 163.00 Mil | 166.00 Mil | 0 | Affirmed | Guidance: 163.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 75.20 Mil | 78.24 Mil | 81.34 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 47.0% | 48.0% | 49.0% | 0 | Affirmed | Guidance: 48.0% for 2026 | |
| 2026 Operating Expenses | Reported | 100.00 Mil | 102.50 Mil | 105.00 Mil | 0 | Affirmed | Guidance: 102.50 Mil for 2026 | |
| 2026 Operating Income | Calculated | -29.80 Mil | -24.26 Mil | -18.66 Mil | Rev x Gross Margin - Opex | |||
| 2026 Operating Margin | Calculated | -18.62% | -14.88% | -11.24% | Implied by guided Rev/GM/Opex | |||
Q4 2025 Earnings Reported 3/17/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 33.00 Mil | 34.00 Mil | 35.00 Mil | -18.1% | Lower New | Guidance: 41.50 Mil for Q4 2025 | |
| 2026 Operating Cash Flow | Reported | -17.00 Mil | -15.00 Mil | -13.00 Mil | ||||
| 2026 Revenue | Reported | 160.00 Mil | 163.00 Mil | 166.00 Mil | 9.8% | Higher New | Guidance: 148.50 Mil for 2025 | |
| 2026 Gross Profit | Calculated | 75.20 Mil | 78.24 Mil | 81.34 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 47.0% | 48.0% | 49.0% | 0 | Same New | Guidance: 48.0% for 2025 | |
| 2026 Operating Expenses | Reported | 100.00 Mil | 102.50 Mil | 105.00 Mil | 0 | Same New | Guidance: 102.50 Mil for 2025 | |
Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Operating Cash Flow | Reported | -2.00 Mil | 0 | 2.00 Mil | ||||
| Q4 2025 Revenue | Reported | 40.00 Mil | 41.50 Mil | 43.00 Mil | ||||
| 2025 Total Cash | Reported | 32.00 Mil | 34.00 Mil | 36.00 Mil | 28.3% | Raised | Guidance: 26.50 Mil for 2025 | |
| 2025 Revenue | Reported | 147.00 Mil | 148.50 Mil | 150.00 Mil | -2.3% | Lowered | Guidance: 152.00 Mil for 2025 | |
| 2025 Gross Profit | Calculated | 69.09 Mil | 71.28 Mil | 73.50 Mil | Rev x Gross Margin | |||
| 2025 Gross Margin | Reported | 47.0% | 48.0% | 49.0% | -1.0% | Lowered | Guidance: 49.0% for 2025 | |
| 2025 Operating Expenses | Reported | 100.00 Mil | 102.50 Mil | 105.00 Mil | 0 | Affirmed | Guidance: 102.50 Mil for 2025 | |
Insider Activity
Updated 7/23/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chernett, Jorey | Direct | Buy | 7152026 | 1.78 | 35,000 | 62,300 | 18,848,399 | Form | |
| 2 | Chernett, Jorey | Direct | Buy | 5202026 | 1.17 | 100,000 | 117,000 | 12,348,166 | Form | |
| 3 | Chernett, Jorey | Direct | Buy | 5132026 | 1.34 | 475,000 | 636,500 | 14,008,344 | Form | |
| 4 | Chernett, Jorey | Direct | Buy | 4222026 | 1.51 | 100,000 | 151,000 | 15,068,272 | Form | |
| 5 | Chernett, Jorey | Direct | Buy | 4222026 | 1.58 | 100,000 | 158,000 | 15,608,801 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chernett, Jorey | Direct | Buy | 7152026 | 1.78 | 35,000 | 62,300 | 18,848,399 | Form | |
| 2 | Chernett, Jorey | Direct | Buy | 5202026 | 1.17 | 100,000 | 117,000 | 12,348,166 | Form | |
| 3 | Chernett, Jorey | Direct | Buy | 5132026 | 1.34 | 475,000 | 636,500 | 14,008,344 | Form | |
| 4 | Chernett, Jorey | Direct | Buy | 4222026 | 1.51 | 100,000 | 151,000 | 15,068,272 | Form | |
| 5 | Chernett, Jorey | Direct | Buy | 4222026 | 1.58 | 100,000 | 158,000 | 15,608,801 | Form | |
| 6 | Chernett, Jorey | Direct | Buy | 3302026 | 1.25 | 385,442 | 481,802 | 12,223,735 | Form | |
| 7 | Chernett, Jorey | Direct | Buy | 3302026 | 1.35 | 500,000 | 675,000 | 12,680,923 | Form | |
| 8 | Chernett, Jorey | Direct | Buy | 3272026 | 1.44 | 25,000 | 36,000 | 12,806,317 | Form | |
| 9 | Chernett, Jorey | Direct | Buy | 3272026 | 1.40 | 125,000 | 175,000 | 12,415,586 | Form | |
| 10 | Chernett, Jorey | Direct | Buy | 3232026 | 1.41 | 169,472 | 238,956 | 12,328,019 | Form | |
| 11 | Chernett, Jorey | Direct | Buy | 3202026 | 1.33 | 450,000 | 598,500 | 11,403,159 | Form | |
| 12 | Chernett, Jorey | Direct | Buy | 3202026 | 1.35 | 607,400 | 819,990 | 10,967,135 | Form | |
| 13 | Chernett, Jorey | Direct | Buy | 3182026 | 1.16 | 531,000 | 615,960 | 8,719,029 | Form | |
| 14 | MacAn, William Andrew | EVP, CLO and CS | Direct | Sell | 3062026 | 1.34 | 609 | 816 | 1,178,564 | Form |
| 15 | MacAn, William Andrew | EVP, CLO and CS | Direct | Sell | 2272026 | 1.35 | 3,427 | 4,626 | 1,188,181 | Form |
| 16 | Sullivan, Keith J | President and CEO | Direct | Sell | 2272026 | 1.35 | 8,452 | 11,410 | 2,058,363 | Form |
| 17 | Sullivan, Keith J | President and CEO | Direct | Sell | 2182026 | 1.65 | 33,847 | 55,848 | 2,529,722 | Form |
| 18 | MacAn, William Andrew | EVP, CLO and CS | Direct | Sell | 2182026 | 1.65 | 14,120 | 23,298 | 1,111,376 | Form |
| 19 | MacAn, William Andrew | EVP, CLO and CS | Direct | Sell | 2122026 | 1.55 | 3,485 | 5,402 | 1,065,906 | Form |
| 20 | Sullivan, Keith J | President and CEO | Direct | Sell | 2122026 | 1.55 | 40,976 | 63,513 | 2,428,869 | Form |
| 21 | Madryn, Asset Management, LP | See footnotes | Sell | 8122025 | 3.72 | 3,500,000 | 13,020,000 | 4,249,546 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/12/2026